Danco Laboratories (Danco) Seeks Supreme Court Stay on Mifepristone Ruling

Danco Laboratories filed an application with the U.S. Supreme Court on March 23, 2024, seeking to halt an appeals court ruling that blocks mail-order access to the abortion drug mifepristone. The ruling, issued by a conservative three-judge panel, significantly limits access nationwide amidst challenges related to the drug's safety. The 2023 FDA regulation allowing mail prescriptions is under scrutiny, with only 2% of prescriptions filled in-person according to USC research. This case has substantial implications for abortion access in states where it is legal, as well as potential impacts on Danco's market position, given Mifeprex is its only product.